Clinical Trials Directory

Trials / Completed

CompletedNCT01225406

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy

Status
Completed
Phase
Study type
Observational
Enrollment
56 (actual)
Sponsor
The HIV Netherlands Australia Thailand Research Collaboration · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is an observational cohort study of virologic and immunologic outcome after at least 48 weeks of third line antiretroviral therapy. Upto 150 children at 8 Thai sites will be enrolled. Third line antiretroviral therapy in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will help the Thai government in planning its strategy to provide third line ARV therapy to children within the national program.

Detailed description

The primary objective of this study is to assess the virological efficacy, as measured by the proportions of children with HIV RNA below 400 and 50 copies/ml at 48 weeks after initiating third line ARV therapy. Third line ARV therapy is defined as an ARV regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir

Conditions

Interventions

TypeNameDescription
DRUGTenofovir

Timeline

Start date
2010-08-01
Primary completion
2013-08-01
Completion
2013-12-01
First posted
2010-10-21
Last updated
2020-07-17

Locations

9 sites across 1 country: Thailand

Source: ClinicalTrials.gov record NCT01225406. Inclusion in this directory is not an endorsement.